ShiraTronics, Inc. Completes $3 Million Additional Series A Financing

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

How To Control a Radio Frequency (RF) Process

The radio frequency welding and manufacturing process uses electromagnetic energy and pressure to fuse and permanently bond vinyl, thermoplastic, and coated materials to produce a specific product - all according to customer requirements. Using this RF sealing process, a distinct, one-piece perpetual bond is formulated that is both solid and resistant to ripping or tearing. But how is this process controlled, and with what specific tools? Read on.

The financing was provided by Breakout Ventures (BOV). BOV joins previous Series A lead investors USVP, Amzak Health, and Strategic HealthCare Investment Partners (S.H.I.P), with participation from Aperture Ventures, LivaNova PLC, and a leading Academic Institution.

“Breakout Ventures backs bold companies bringing the strongest scientific insights to bear on important problems. ShiraTronics’ approach builds on years of clinical evidence for the effectiveness of neuromodulation, when properly administered, in the treatment of chronic migraine. We believe the time is right to build a safe, convenient system dedicated to this purpose and that the team behind it has the experience needed to succeed,” said Lindy Fishburne, Breakout Ventures’ Managing Partner.  “We are honored to join an investor syndicate with deep expertise in commercializing medical devices to further accelerate ShiraTronics’ path to market, and ultimately to patients.”

“We are thrilled to be partnered with such an experienced investor group led by USVP, Amzak, and S.H.I.P. This important financing from Breakout Ventures provides us additional resources needed to develop and advance a novel therapy for migraine headache in the clinic,” said Lynn Elliott the President and Chief Executive Officer of ShiraTronics.

“Our therapy under development for migraine, a condition that disproportionately impacts women, has the potential to positively impact the lives of millions of patients worldwide. We warmly welcome the addition of Breakout Ventures to this world-class consortium of investors to further develop this valuable therapy,” said Mudit K. Jain, Ph.D., a co-founder and Chairman of the Board of ShiraTronics.

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.